Active substanceButylamine hydroxypropoxyphenoxymethyl methyl oxadiazoleButylamine hydroxypropoxyphenoxymethyl methyl oxadiazole
Similar drugsTo uncover
Dosage form: & nbspEye drops.
Composition:
Composition for 1 ml.

Active substance: butylaminohydroxy-propoxyphenoxymegal methyloxadiazole-10 mg.

Excipients: benzethonium chloride - 0.1 mg Sodium chloride - 7.0 mg citric acid monohydrate - 0.33 mg of sodium citrate - 6.49 mg Water for injection - up to 1 ml.
Description:
Transparent colorless or slightly colored liquid.

Pharmacotherapeutic group:Antiglaucoma means - alpha and beta adrenoblocker.
ATX: & nbsp

S.01.E.X   Other antiglaucoma drugs

C.07.A.G.   Alpha-, beta-blockers

Pharmacodynamics:Proxodolol is a non-selective alpha-and beta-adrenoblocker. The drug reduces intraocular pressure, which is due to a decrease in the production of aqueous humor and the relief of its outflow. The hypotensive effect of the drug in respect of intraocular pressure occurs within 15-30 minutes after installation, reaching a maximum after 4-6 h Duration of effect -. 24 hours.The drug does not affect the accommodation, refraction and size of the pupil, does not have a local irritant effect. In an insignificant amount enters the systemic bloodstream through absorption through the mucous membrane of the eye, nose and tear duct, causes a systemic effect characteristic of adrenoblockers.
Indications:Primary open and closed angle glaucoma, secondary glaucoma.
Contraindications:Hypersensitivity.
Carefully:Chronic obstructive pulmonary disease, bronchial asthma, chronic heart failure, sinus bradycardia, atrioventricular blockade of II-III degree, cardiogenic shock, type 1 diabetes, peptic ulcer and duodenal ulcer.
Dosing and Administration:Bury in the conjunctival sac 1-2 drops of 1% solution 2-3 times a day. At the beginning of treatment, a 1% solution of proxodolol is prescribed. If the 1% solution is ineffective, a 2% solution of proxodolol is used.
Side effects:Bradycardia, AV blockade, lowering of arterial pressure, bronchospasm; dizziness, weakness, nausea; local reactions - burning (within 15-20 s); allergic reactions (local or generalized exanthema, urticaria).
Interaction:Strengthens the action of pilocarpine and clonidine on intraocular pressure. With the simultaneous administration of systemic alpha or beta-adrenoblockers, an increase in the hypotensive effect is possible.
Special instructions:During treatment, you should not wear soft contact lenses.
Form release / dosage:Eye drops 1%.
Packaging:5 ml or 10 ml in polyethylene bottles with plugs-droppers and screw-on caps (bottle-dropper polymer). Each vial with instructions for use in a pack of cardboard.
Storage conditions:In a dark place at a temperature of no higher than 25 ° C. Keep out of the reach of children.
Shelf life:
2 years. After opening the vial, use within 1 month.

Do not use after the expiry date printed on the package.
Terms of leave from pharmacies:On prescription
Registration number:P N001067 / 01
Date of registration:16.01.2008/20.01.2013
The owner of the registration certificate:SYNTHESIS, OJSC SYNTHESIS, OJSC Russia
Manufacturer: & nbsp
Information update date: & nbsp06.04.2016
Illustrated instructions
    Instructions
    Up